Last reviewed · How we verify
CYT-0851 in combination with gemcitabine
CYT-0851 in combination with gemcitabine is a Small molecule drug developed by Cyteir Therapeutics, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | CYT-0851 in combination with gemcitabine |
|---|---|
| Sponsor | Cyteir Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CYT-0851 in combination with gemcitabine CI brief — competitive landscape report
- CYT-0851 in combination with gemcitabine updates RSS · CI watch RSS
- Cyteir Therapeutics, Inc. portfolio CI
Frequently asked questions about CYT-0851 in combination with gemcitabine
What is CYT-0851 in combination with gemcitabine?
CYT-0851 in combination with gemcitabine is a Small molecule drug developed by Cyteir Therapeutics, Inc..
Who makes CYT-0851 in combination with gemcitabine?
CYT-0851 in combination with gemcitabine is developed by Cyteir Therapeutics, Inc. (see full Cyteir Therapeutics, Inc. pipeline at /company/cyteir-therapeutics-inc).
What development phase is CYT-0851 in combination with gemcitabine in?
CYT-0851 in combination with gemcitabine is in Phase 1.